For example, strategies to inhibit the expression of c-FLIP variants not only trigger apoptosis in certain cancer types, but also sensitize cancer cells to chemotherapeutic agents, potentially allowing lower doses to be administered to patients and decreasing drug-induced systemic toxicities. Here, CFLAR is linked to cancer.